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Purpose
Antiviral drugs are standard treatment for chronic hepa-
titis B. In traditional Chinese medicine practice, admin-
istration of drugs through acupuncture point (acupoint)
is considered better than intramuscular injection or
intravenous infusion. In this review, we evaluated com-
parative effects and safety of antiviral drugs through
acupoint injection versus other administration for treat-
ment of chronic hepatitis B.
Methods
We systematically searched PubMed, the Cochrane
Library, the Cochrane Hepato-Biliary Group Trial Regis-
ter, and four Chinese electronic databases through
March 2011 to identify randomized controlled trials
(RCTs) comparing acupoint injection with intramuscu-
lar, subcutaneous injection or intravenous infusion for
at least three months for treatment of chronic hepatitis
B. The quality of the RCTs was assessed using the
Cochrane risk of bias tool and data were synthesized
using RevMan 5.
Results
Ten RCTs involving 1618 people with chronic hepatitis
B were included. Three of 10 RCTs were rated as having
low risk of bias and the remaining trials as high or
uncertain risk of bias. Acupoint injection of interferon-
alpha showed significantly better effect on the loss of
serum HBeAg than intramuscular injection (RR 1.37,
95% confidence interval (CI) 1.10 to 1.70; 3 trials). Simi-
larly, acupoint injection of interferon-alpha was better
than intravenous infusion for loss of serum HBeAg (RR
2.38, 95% CI 1.17 to 4.83; 3 trials). However, there was
no significant difference between acupoint and intra-
muscular injection of interferon-alpha in terms of the
loss of serum HBsAg or HBV DNA. Acupoint injection
of poly I-C, or matrine showed beneficial effects on loss
of serum HBeAg compared with intramuscular injection.
Acupoint injection of antiviral drugs did not report
extra adverse effects from the included trials.
Conclusion
Acupoint injection of antiviral drugs for three months
treatment for chronic hepatitis B may have more benefi-
cial effects than intramuscular or intravenous injection.
However, the findings need to be confirmed in large,
rigorous randomized trials.
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